Clinical Trials
20
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
10
50.0%
Not yet recruiting
2
10.0%
Recruiting
5
25.0%
Unknown
1
5.0%
Withdrawn
2
10.0%
No approval data available
- BVI's FINEVISION HP trifocal intraocular lens has received FDA approval for the US market, expanding advanced IOL options for American ophthalmologists and their patients. - The lens has been implanted in millions of procedures globally over 15 years and features diffractive optic design supporting vision at far, intermediate, and near distances. - A phased US rollout is planned starting fall 2025, with broader distribution expected in the first six months of 2026 as BVI scales manufacturing to meet anticipated demand. - The approval is supported by US clinical study data (NCT04176965) and represents a significant expansion of BVI's premium IOL portfolio in the American market.
- Dr. John Berdahl of Vance Thompson Vision discussed the promising clinical trial results of travoprost, offering new insights into its efficacy. - Meghan Berkenstock presented data on the incidence and prevalence of uveitis and associated ocular complications using the US TriNetX Database. - Dr. Michael Singer shared research findings on the effectiveness of gel versus traditional drops for anesthesia during intravitreal injections, highlighting potential benefits.
